글로벌 게놈 편집 시장은 2021년부터 2029년까지 18.5% 이상의 CAGR로 성장할 것으로 예상됩니다. 2020년 32억 5천만 달러에서 2029년까지 145억 6천만 달러 이상으로 성장할 것으로 예상됩니다.
게놈 편집 시장은 세포나 유기체의 DNA에 특정한 변화를 주는 정밀한 방법인 게놈 편집과 관련된 기술 및 제품 시장을 말합니다. CRISPR -Cas9, TALEN, 아연 손가락 뉴클레아제와 같은 게놈 편집 기술을 사용하면 과학자들이 전례 없는 정밀도로 유기체의 DNA 서열을 수정할 수 있습니다. 이러한 기술은 농업, 의료, 생명공학 , 연구를 포함한 다양한 분야에서 광범위하게 응용됩니다 . 농업에서 게놈 편집은 수확량, 질병 저항성, 환경 스트레스 내성이 향상된 작물을 개발하는 데 사용할 수 있습니다. 의료에서 게놈 편집은 질병을 유발하는 유전자를 교정하거나 수정하여 유전적 질환, 암, 감염성 질환을 치료하는 데 유망합니다.
시장 확대는 주로 합성 유전자에 대한 수요 증가와 다양한 생명공학 분야에서 CRISPR 게놈 편집 기술의 광범위한 채택에서 비롯됩니다. 또한 예상되는 성장은 정부 자금 지원 증가, 유전자 변형 작물 생산 증가, 게놈 프로젝트 증가에 의해 주도될 것으로 예상됩니다.
시장 성장은 합성 생물학에 대한 유리한 정부 규제, 조작된 유전자와 세포에 대한 수요 증가, 정부 기관과 주요 기업의 투자 증가로 인해 촉진되었습니다. 게다가 치료 목적을 위한 비전통적 유전자 편집 기술의 발견과 적용은 유전자 치료와 분자 생물학에서 상당한 진전을 나타내며, 시장 확장에 더욱 기여합니다.
또한, 사용자 친화적인 유전자 치료 시스템의 가용성, 게놈 공학의 발전, 유전자 기능에 대한 신속한 전체 게놈 분석을 용이하게 하는 유전자 치료의 잠재력은 모두 예측 기간 동안 시장 성장에 기여합니다.
On the basis of technology type, the global genome editing market has been segmented as – CRISPR, Talen, ZFN, and other genome editing or genetic editing technologies. CRISPR is a powerful tool for editing genomes, denotation it allows researchers to easily modify DNA sequences and change gene function. It has many potential applications, including amending genetic defects, treating and preventing the spread of diseases, and improving the growth and resilience of crops.
Talen can be used to edit genomes by encouraging double-strand breaks (DSB), which cells respond to with repair mechanisms. Non-homologous end joining (NHEJ) directly ligates DNA from either side of a double-strand break where there is very slight or no sequence overlap for annealing. Zinc Finger Nucleases (ZFNs) are a class of engineered DNA-binding proteins that enable targeted editing of the genome by creating double-strand breakdowns in DNA at user-specified locations. The other technologies category includes antisense technology and mega nucleases.
Based on application, the genome editing market is divided into five segments, gene therapy, disease models, functional genomics, knockdown/activation and other applications. Genetic engineers have developed genetic recombination techniques or genome editing techniques to manipulate gene sequences in plants, animals and other organisms to express specific traits. Applications for genetic editing are increasing as engineers and scientists work together to identify the locations and functions of specific genes in the DNA sequence of various organisms.
A laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. This method can be used to find changes in areas of the genome. These changes may help scientists understand how specific diseases form. Functional genomics involves learning the expression and function of the genome. Genomics can also comprise the investigation of interactions between genes and between genes and the environment.
End user segment of the global genome editing market includes academic & government research institutes, biotechnology & pharmaceutical companies, contract research organizations, and other end users. Biotechnology and pharmaceutical companies are one of the major end users of the genome editing market. These companies are incorporating numerous CRISPR gene editing products and services for the treatment and screening of genetic disorders. Gene therapy holds potential for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.
Abcam, Inc., is one of the emerging players in the CRISPR gene editing market. The global life sciences company develops biological reagents and tools required in drug discovery, basic research, diagnostics, and other fields and applications. The company offers research-based only proteomic tools, antibodies, protein binding reagents, and immunoassays to researchers and scientists in academic institutes, biotechnology, diagnostics, and pharmaceuticals companies for studying biological pathways critical in scientific research, drug discovery, and diagnostics.
Applied StemCell, Inc., headquartered in California, US, is one of the emerging private players in the gene editing market. The company develops gene modification technologies enabling stem cell and genome editing to augment revolutionary biomedical and industrial research and applications. The company’s competitors that cater to the CRISPR gene editing market include System Biosciences LLC, Horizon Discovery Group PLC, Takara Bio, GeneCopoeia, Inc., and Cellecta, Inc., among others.
The genome editing market by region includes North America, Europe, Asia-Pacific (APAC), South America, and Middle East & Africa (MEA). The North America region is currently dominating the global genome editing market. Several conglomerate and small-medium enterprises are focused on collaborating with each other and other distributing channels to expand their global reach by developing more cost-effective and advanced products is consequentially promoting the growth of the global genome editing market.
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.